Ertugliflozin for type 2 diabetes mellitus
|
|
- Eleanor Richardson
- 5 years ago
- Views:
Transcription
1 October 2016 Horizon Scanning Research & Intelligence Centre Ertugliflozin for type 2 diabetes mellitus NIHR HSRIC ID: 7712; 11910; 12223; Lay summary Ertugliflozin is a new drug to treat type 2 diabetes. Type 2 diabetes is a disease that results when the level of sugar in the blood is too high. This can cause damage to the eyes, nerves, kidneys and other tissues. It also greatly increases the chance of heart attacks and strokes. Ertugliflozin is taken as a tablet once a day and works by increasing the amount of sugar that passes out of the body in urine. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. Horizon Scanning Research & Intelligence Centre University of Birmingham nihrhsric@contacts.bham.ac.uk
2 TARGET GROUP Diabetes mellitus: type 2; in adults aged 18 years and older; in patients for whom diet and exercise do not provide adequate glycaemic control As monotherapy, in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications. As add-on combination therapy, with other glucose-lowering medicinal products, including insulin. TECHNOLOGY DESCRIPTION Ertugliflozin (MK-8835; PF ) is an orally active inhibitor of the sodium glucose cotransporter type 2 (SGLT2). SGLT2 is responsible for 80-90% of renal glucose re-absorption and is often overexpressed and over activated in patients with type 2 diabetes. SGLT2 inhibitors reduce renal glucose reabsorption in the proximal convoluted tubule, leading to increased urinary glucose excretion 1. In phase III clinical trials, ertugliflozin is administered orally at 5mg or 15mg once daily 2. Ertugliflozin does not currently have Marketing Authorisation in the EU for any indication. INNOVATION and/or ADVANTAGES If licensed, ertugliflozin will offer an additional treatment option for patients with type 2 diabetes mellitus. DEVELOPER Merck Sharp and Dohme AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND Type 2 diabetes mellitus is a chronic metabolic disorder, the prevalence of which has been increasing steadily in all parts of the world 3. Type 2 diabetes mellitus consists of an array of dysfunctions characterised by hyperglycaemia (glycosylated haemoglobin [HbA1c] >48mmol/mol or random plasma glucose >11mmol/L), resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion 4,5. Type 2 diabetes is the most common form of diabetes, accounting for about 90% of cases 5. Symptoms of type 2 diabetes include polyuria, polydipsia, polyphagia, weight loss, blurred vision, paraesthesia of the lower extremities and yeast infections 4,6.
3 Complications of type 2 diabetes include 5a : Microvascular complications retinopathy, nephropathy and neuropathy. Macrovascular complications cardiovascular disease, cerebrovascular disease, and peripheral arterial disease. Metabolic complications dyslipidaemia, hyperosmolar state, and diabetic ketoacidosis. Psychological complications including anxiety and depression. Type 2 diabetes is due primarily to lifestyle and genetic factors. A number of lifestyle factors are known to be important to the development of this condition, such as physical inactivity, poor diet, cigarette smoking and excessive consumption of alcohol 3,a. Obesity has been found to contribute to approximately 55% of cases of type 2 diabetes 3. There is a strong heritable genetic predisposition; having relatives with type 2 diabetes increases the risks substantially. The risk of developing type 2 diabetes is about 15% if one parent has type 2 diabetes and 75% if both parents have type 2 diabetes 5. However, individually these account for only a small proportion of cases. Lifestyle interventions (such as diet and physical activity) are recommended initially to manage type 2 diabetes and reduce the risk of complications. However, over time, many people will require antidiabetic drug treatments 5. CLINICAL NEED and BURDEN OF DISEASE It is estimated that more than 1 in 16 people in the UK has diabetes (diagnosed or undiagnosed), which equates to approximately 4 million people aged 16 years and over in England, of whom around 90% have type 2 diabetes 7,8. By 2035, it is estimated that 4.9 million people will have diabetes in England 8. People from South Asian and Black communities are two to four times more likely to develop type 2 diabetes than those from White ethnic groups 7. In , there were 20,971 hospital admissions for type 2 diabetes (ICD-10 E11) in England, resulting in 153,939 bed days and 34,028 finished consultant episodes 9. In the same year in England and Wales, 2,435 deaths were registered for type 2 diabetes (ICD-10 E11) 10. Diabetes is costly to the NHS, with a recent study estimating that 10% of all NHS expenditure is for diabetes 11. In , it was estimated that 9.5% of prescribing costs were for diabetes, including pharmaceutical treatment and blood glucose testing strips 12. Cardiovascular disease is a major cause of death and disability in people with diabetes, accounting for 52% of deaths in people with type 2 diabetes 7. There is a 139% increased risk of angina, a 94% increased risk of myocardial infarction, a 126% increased risk of heart failure, and a 63% increased risk of stroke among people with diabetes 7. People with type 2 diabetes have a two-fold increased risk of stroke within the first five years of diagnosis compared with the general population 7. Around one fifth of hospital admissions for heart failure, heart attack and stroke are in people with diabetes 7. It is estimated that 56% of patients receiving pharmacological treatment for type 2 diabetes are receiving first-line treatment, which equates to approximately 1.2 million people in England. It is also estimated that 25% of patients receiving pharmacological treatment for type 2 diabetes are receiving second-line treatment, which equates to approximately 517,000 people in England 13. a Expert personal communication. 3
4 PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Diabetes (type 2) dapagliflozin (with metformin and a sulfonylurea) (ID962). Expected January NICE technology appraisal in development. Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) (ID756). Expected May NICE technology appraisal. Empagliflozin in combination therapy for treating type 2 diabetes (TA336). March NICE technology appraisal. Canagliflozin in combination therapy for treating type 2 diabetes (TA315). June NICE technology appraisal. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288). June NICE technology appraisal. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151). July NICE guidelines. Type 2 diabetes: management (NG28). December NICE guidelines. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18). August NICE clinical guideline. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181). July NICE public health guidance. Type 2 diabetes: prevention in people at high risk (PH38). July NICE public health guidance. Type 2 diabetes prevention: population and communitylevel interventions (PH35). May NICE quality standard. Diabetes in adults (QS6). March NHS England Policies and Guidance NHS England. 2013/14 NHS Standard Contract for Insulin-Resistant Diabetes Services (All Ages). A17/S(HSS)/b. Other Guidance British Medical Journal. Management of type 2 diabetes in adults: summary of updated NICE guidance International Diabetes Federation. Diabetes eye health: a guide for health care professionals Joint British Diabetes Societies Inpatient Care Group. Management of adults with diabetes undergoing surgery and elective procedures: improving standards Scottish Intercollegiate Guidelines Network. Management of diabetes (116) NHS University Hospitals Leicester. Diabetes mellitus guidelines Trend UK. Diabetes and Dementia Guidance on Practical Management International Diabetes Federation. Managing older people with type 2 diabetes The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines Royal College of Nursing. Starting injectable treatment in adults with Type 2 diabetes
5 International Diabetes Federation. Global guideline for type 2 diabetes Diabetic Medicine. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis CURRENT TREATMENT OPTIONS Treatments for type 2 diabetes should adopt an individualised approach that is tailored to the needs and circumstances of the patient, taking into account their personal preferences, comorbidities, risks from polypharmacy, and ability to benefit from long-term interventions because of reduced life expectancy 25. Educating the patient in managing their diabetes, alongside dietary advice, and weight loss targets for patients who are overweight is often the first approach in managing this condition 14,25. Pharmacological treatment options include 14,25 : Standard-release metformin is the initial drug offered. The dose is gradually increased over several weeks to minimise the risk of gastrointestinal side effects. If gastrointestinal effects do occur, a modified-release formulation of metformin can be trialled. If metformin is contraindicated or not tolerated, the initial recommended treatment options are dipeptidyl peptidase-4 inhibitor (DPP-4, or gliptin ), pioglitazone or sulfonylurea. Pioglitazone should not be offered to diabetic patients with a history of heart failure, hepatic impairment, diabetic ketoacidosis, bladder cancer, or macroscopic haematuria. Drug treatment intensification with metformin in combination with either a DPP-4 inhibitor, pioglitazone, sulfonylurea or SGLT2 inhibitor (such as canagliflozin, dapagliflozin and empagliflozin), is recommended for patients whose HbA1c has not been controlled by metformin alone. For patients who are not taking metformin as the initial drug treatment, combinations of either a DPP-4 inhibitor, pioglitazone or sulfonylurea, or SGLT2 inhibitor can be used. If dual therapy with metformin and other oral drugs is insufficient, triple therapy with a combination of metformin, DPP-4 inhibitor, pioglitazone, sulfonylurea, or SGLT2 inhibitor may be used. A structured programme of insulin therapy may be offered in combination with continuing support and self-monitoring if triple therapy has not been effective. Insulin based therapy may be used in combination with any of the aforementioned drugs. EFFICACY and SAFETY Trial NCT , , , B ; ertugliflozin vs placebo; phase III. NCT , , , B ; ertuglizflozin in combination with sitagliptin vs placebo; phase III. Merck Sharp & Dohme NCT , , , B ; ertugliflozin vs glimepiride; phase III. Sponsor Merck Sharp & Dohme Merck Sharp & Dohme Status Complete but unpublished. Complete but unpublished. Ongoing. Source of Trial registry 2, Trial registry 26, Trial registry 27, information manufacturer. manufacturer. manufacturer. Location EU (incl UK), USA, Canada EU (incl UK), USA and EU (not UK), USA, Canada and other countries. other countries. and other countries. Design Randomised, placebocontrolledcontrolled. Randomised, placebo- Randomised, activecontrolled. 5
6 Participants n=464; aged 18 yrs and older; type 2 diabetes mellitus; no oral antihyperglycaemic agents for at least 8 wks prior to study participation. n=292; aged 18 yrs and older; type 2 diabetes mellitus; no oral antihyperglycaemic agents for at least 8 wks prior to study participation and HbA1c 8% and 10.5%; or on a single allowable antihyperglycaemic agent (metformin, α-glucosidase inhibitors, sulfonylureas and glinides) and HbA1c 7.5% and 10%; or on low dose dual combination therapy with allowable antihyperglycaemic agents and HbA1c 7.5% and 10%. n=1,230 (planned); aged 18 yrs and older; type 2 diabetes mellitus; on metformin monotherapy or metformin in combination with a single allowable antihyperglycaemic agent (dipeptidyl peptidase-4 inhibitor, glinides and α- glucosidase inhibitors). Schedule Part A: Randomised to ertugliflozin 5mg oral once daily for 26 wks; or ertugliflozin 15mg oral once daily; or placebo once daily for 26 Part B: Pts requiring rescue with metformin in part A continue to receive metformin in addition to their original randomised treatment, once daily for 26 Pts not requiring rescue with metformin in part A receive metformin placebo in addition to their original randomised treatment, once daily for 26 Follow-up Active treatment for 52 Primary HbA1c; adverse effects outcomes (AEs). Secondary Fasting plasma glucose, outcomes body weight, 2-hrs postprandial plasma glucose, and blood pressure; number of pts with HbA1c <7%. Randomised to ertugliflozin 5mg oral once daily for 26 wks; or ertugliflozin 15mg oral once daily; both in combination with sitagliptin 100mg oral once daily; or ertugliflozin placebo and sitagliptin placebo oral once daily for 26 Active treatment for 26 HbA1c; AEs. Fasting plasma glucose, body weight, 2-hrs postmeal glucose, body weight, and blood pressure; number of pts with HbA1c <7%. Randomised to ertugliflozin 5mg oral once daily; or ertugliflozin 15mg oral once daily; or glimepiride 8mg oral once daily. Active treatment for 26 HbA1c; AEs. Body weight; systolic blood pressure; number of pts with symptomatic hypoglycaemia. Key results Not reported. Not reported. - Adverse Not reported. Not reported. - effects (AEs) Expected reporting date Previously reported as July Previously reported as Feb Study completion date reported as April
7 Trial NCT , , , B ; ertugliflozin vs placebo; phase III. Sponsor Merck Sharp & Dohme NCT , ; ertugliflozin vs sitagliptin; phase III. NCT , , , B ; ertugliflozin vs placebo; phase III. Merck Sharp & Dohme Merck Sharp & Dohme Status Ongoing. Complete but unpublished. Complete but unpublished. Source of Trial registry 28, Trial registry 29, Trial registry 30, information manufacturer. manufacturer. manufacturer. Location EU (incl UK), USA and EU (incl UK), USA, EU (not UK), USA and other countries. Canada and other other countries. Design Randomised, placebocontrolled. Participants n=600 (planned); aged 18 yrs and older; type 2 diabetes mellitus; on metformin monotherapy for <8 wks prior to study participation; HbA1c 7% and 10.5%. Schedule Randomised to ertugliflozin 5mg oral once daily; or ertugliflozin 15mg once daily; or placebo oral once daily; all in combination with metformin 1,500mg oral once daily. countries. Randomised, activecontrolled. n=1,291; aged 18 yrs and older; type 2 diabetes mellitus; on metformin monotherapy ( 1,500mg/day) with HbA1c 7.5% and 11%; or on metformin monotherapy (<1,500mg/day) with HbA1c 8% and 11.5%. Randomised to ertugliflozin 5mg oral once daily; or ertugliflozin 15mg oral once daily; or ertugliflozin 5mg once daily in combination with sitagliptin 100mg oral once daily; or ertugliflozin 15 mg once daily in combination with sitagliptin 100mg oral once daily; or sitagliptin 100mg oral once daily; all in combination with metformin 1,500mg oral once daily. Randomised, placebocontrolled. n=462; aged 18 yrs and older; type 2 diabetes; on stable dose of metformin with either sitagliptin or another dipeptidyl peptidase-4 inhibitor or a sulfonylurea. Randomised to ertugliflozin 5mg oral once daily; or ertugliflozin 15mg oral once daily; or placebo oral once daily. Pts are to remain on their stable doses of metformin and sitagliptin, and receive glimepiride and insulin glargine rescue medication as required. Follow-up Active treatment for 104 Active treatment for 52 Active treatment for 52 Primary HbA1c; AEs. HbA1c; AEs. HbA1c; AEs. outcomes Secondary outcomes Fasting plasma glucose, body weight, blood pressure, bone mineral density, and bone biomarkers; number of pts with HbA1c <7%; number of pts with HbA1c <6.5%; number of pts requiring glycaemic rescue therapy. Fasting plasma glucose, body weight, blood pressure and beta-cell function; number of pts with HbA1c <7%. Fasting plasma glucose, body weight, and blood pressure; number of pts with HbA1c <7%. Key results - Not reported. Not reported. AEs - Not reported. Not reported. Expected reporting date Study completion date reported as Aug Previously reported as May Previously reported as June
8 ESTIMATED COST and IMPACT COST The cost of ertugliflozin is not yet known. The cost of other selected treatments for type 2 diabetes include 31 : Drug Dose Annual cost Metformin 1,500mg oral once daily Sitagliptin 100mg oral once daily Glimepiride 4mg oral once daily Empagliflozin 10mg oral once daily IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Other Reduced symptoms or disability No impact identified Impact on Health and Social Care Services Increased use of existing services Re-organisation of existing services Other Decreased use of existing services Need for new services None identified Impact on Costs and Other Resource Use Increased drug treatment costs Other increase in costs Other: uncertain unit cost compared to existing alternative treatment options. Reduced drug treatment costs Other reduction in costs None identified Other Issues Clinical uncertainty or other research question identified: expert opinion states that they believe ertugliflozin will add little to an already crowded field of SGLT2 inhibitors. Recent data suggest empagliflozin has a strong link with reduced cardiovascular events and mortality in patients with diabetes and high risk cardiovascular disease. Ertugliflozin will therefore have to demonstrate very significant benefits to be prescribed before other SGLT2 inhibitors b. None identified b Expert personal communication. 8
9 REFERENCES 1 Vasilakou D, Karagiasnnis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Annals of Internal Medicine 2013;159(4): ClinicalTrials.gov. A phase 3, randomised, double-blind, placebo-controlled, 26-week multicentre study with a 26-week extension to evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of subjects with type 2 diabetes mellitus and inadequate glycaemic control despite diet and exercise. Accessed 14 October Olokoba AB, Obateru OA and Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Medical Journal 2012; 27(4): MedScape. Type 2 diabetes Mellitus. Accessed 14 October National Institute for Health and Care Excellence. Clinical knowledge summaries: diabetes type 2. Accessed 14 October NHS Choices. Type 2 diabetes. Accessed 14 October Diabetes UK. Facts and Stats November Stats_Dec% pdf Accessed 14 October Public Health England. Diabetes prevalence model. Accessed 14 October Health & Social Care Information Centre. Hospital episode statistics for England. Inpatient statistics, Office for National Statistics. Mortality statistics: deaths registered in England and Wales, series DR Hex N, Bartlett C. Wright D et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetic Medicine 2012;29(7): Health & Social Care Information Centre. Prescribing for diabetes: England to Accessed 14 October National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal costing template TA288. London: NICE; June McGuire H, Longson D, Adler A et al. Management of type 2 diabetes in adults: summary of updated NICE guidance. British Medical Journal 2016;353:i International Diabetes Federation. Diabetes eye health: a guide for health care professionals. Accessed 14 October Joint British Diabetes Societies for inpatient care. Management of adults with diabetes undergoing surgery and elective procedures: improving standards summary. Revised September Accessed 14 October Scottish Intercollegiate Guidelines Network. Management of diabetes. National clinical guideline 116. Edinburgh: SIGN; September Leicestershire diabetes. Leicestershire Diabetes Guidelines Accessed 14 October Trend UK. Diabetes and Dementia. Guidance on Practical Management Accessed 14 October International Diabetes Federation. Guideline for managing older people with type 2 diabetes. Accessed 14 October The Royal College of Ophthalmologists. Diabetic retinopathy guidelines; December updated-July-2013.pdf Accessed 14 October Royal College of Nursing. Staring injectable treatment in adults with Type 2 diabetes www2.rcn.org.uk/ data/assets/pdf_file/0009/78606/ pdf Accessed 14 October International Diabetes Federation. Global guideline for type 2 diabetes Accessed 14 October Savage MW, Dhatariya KK, Kilvert A et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabetic Medicine 2011;38:
10 25 National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guidelines NG28. London: NICE; December ClinicalTrials.gov. A phase 3, randomised, double-blind, placebo-controlled, parallel-group, multicentre clinical trial to evaluate the efficacy and safety of the initial combination of ertugliflozin with sitagliptin in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on diet and exercise. Accessed 14 October ClinicalTrials.gov. A phase 3, multicentre, randomised, double-blind, active-comparator-controlled clinical trial to study the safety and efficacy of the addition of ertugliflozin compared with the addition of glimepiride in subjects with type 2 diabetes mellitus who have inadequate glycaemic control on metformin. Accessed 14 October ClinicalTrials.gov. A phase 3, randomised, double-blind, placebo-controlled, 26-week multicentre study with a 78-week extension to evaluate the efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus and inadequate glycaemic control on metformin monotherapy. Accessed 14 October ClinicalTrials.gov. A phase 3, randomised, double-blind, multicentre study to evaluate the efficacy and safety of the combination of ertugliflozin with sitagliptin compared with ertugliflozin alone and sitagliptin alone, in the treatment of subjects with type 2 diabetes mellitus with inadequate glycaemic control on metformin monotherapy. Accessed 14 October ClinicalTrials.gov. A phase 3, multicentre, randomised, double-blind, placebo-controlled, parallelgroup clinical trial to evaluate the safety and efficacy of ertugliflozin in the treatment of subjects with type 2 diabetes mellitus who have inadequate glycaemic control on metformin and sitagliptin. Accessed 14 October Joint Formulary Committee. British National Formulary. BNF September BMJ Group and Pharmaceutical Press. 10
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationTechnology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes Technology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572 NICE 2019. All rights reserved. Subject to
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationUK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1
PRESS RELEASE 24 th February, 2014 UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1 London, 24 February 2014
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationSotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus
NIHR Innovation Observatory Evidence Briefing: September 2017 Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus NIHRIO (HSRIC) ID: 8655 NICE ID: 9521 LAY SUMMARY Type 1
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 December 2014 JARDIANCE 10 mg, film-coated tablet B/30 tablets (CIP: 34009 278 928 5 1) JARDIANCE 25 mg, film-coated
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Type 2 diabetes: the management of type 2 diabetes (update) 1.1 Short title Type 2 diabetes (update) 2 Background a) The National
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationEUnetHTA WP5 Joint Action 2 ( ) Strand A, Rapid Relative Effectiveness Assessment of pharmaceuticals
EUnetHTA WP5 Joint Action 2 (2012-2015) Strand A, Rapid Relative Effectiveness Assessment of pharmaceuticals Pilot assessment using the HTA Core Model for Rapid Relative Effectiveness Assessment CANAGLIFLOZIN
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationNational Institute for Health and Care Excellence. Multiple Technology Appraisal (MTA)
Multiple Technology Appraisal (MTA) Dapagliflozin, empagliflozin and sotagliflozin, in combination with Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationSIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes. A national clinical guideline November 2017.
SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes A national clinical guideline November 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE
More informationSummary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationNICE guideline Published: 2 December 2015 nice.org.uk/guidance/ng28
Type 2 diabetes in adults: management NICE guideline Published: 2 December 2015 nice.org.uk/guidance/ng28 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More informationCertolizumab pegol (Cimzia) for chronic plaque psoriasis in adults
NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most
More informationrhngf for neurotrophic keratitis first line
September 2015 Horizon Scanning Research & Intelligence Centre rhngf for neurotrophic keratitis first line LAY SUMMARY This briefing is based on information available at the time of research and a limited
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationDiabetes and stroke. What is the link between diabetes and stroke? What is diabetes? What are the symptoms of diabetes?
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Diabetes and stroke Diabetes is a lifelong condition that occurs when your body cannot regulate the amount of sugar in your blood. If
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationType 2 diabetes in adults
Internal Clinical Guidelines Team Final version : management Clinical Guideline Update (NG28) Methods, evidence and recommendations December 2015 Commissioned by the National Institute for Health and Care
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationNICE BULLETIN Type 2 diabetes in adults: management
NICE BULLETIN Type 2 diabetes in adults: management NICE approved the reproduction of its content for this booklet. NICE is independent of any company or product advertised. TYPE2_DIABETES.indd 1 09/02/2016
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationVolixibat for non-alcoholic steatohepatitis (NASH)
NIHR Innovation Observatory Evidence Briefing: October 2017 Volixibat for non-alcoholic steatohepatitis (NASH) NIHRIO (HSRIC) ID: 10240 NICE ID: 9524 LAY SUMMARY Non-alcoholic steatohepatitis (NASH) is
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationDiabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
open access Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care Julia Hippisley-Cox, Carol Coupland Division of Primary Care, University
More information667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY
667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes...
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More information